Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.creatorMartin-Romano, P. (Patricia)-
dc.creatorCastañon, E. (Eduardo)-
dc.creatorAmmari, S. (Samy)-
dc.creatorChampiat, S. (Stéphane)-
dc.creatorHollebecque, A. (Antoine)-
dc.creatorPostel-Vinay, S. (Sophie)-
dc.creatorBaldini, C. (Capucine)-
dc.creatorVarga, A. (Andrea)-
dc.creatorMichot, J.M. (Jean Marie)-
dc.creatorVuagnat, P. (Perrine)-
dc.creatorMarabelle, A. (Aurelien)-
dc.creatorSoria, J.C. (Jean-Charles)-
dc.creatorFerté, C. (Charles)-
dc.creatorMassard, C. (Christophe)-
dc.identifier.citationMartin-Romano, P. (Patricia); Castañon, E. (Eduardo); Ammari, S. (Samy); et al. "Evidence of pseudoprogression in patients treated with PD1/ PDL1 antibodies across tumor types". Cancer Medicine. 9 (8), 2020, 2643 - 2652es
dc.description.abstractBackground: PD(L)1 antibodies (anti-PD(L)-1) have been a major breakthrough in several types of cancer. Novel patterns of response and progression have been described with anti-PD(L)-1. We aimed at characterizing pseudoprogression (PSPD) among patients with various solid tumor types treated by anti-PD(L)-1. Methods: All consecutive patients (pts) enrolled in phase 1 trials with advanced solid tumors and lymphomas treated in phase I clinical trials evaluating monotherapy by anti-PD(L)-1 at Gustave Roussy were analyzed. We aimed to assess prevalence and outcome of PSPD across tumor types. We also intended to describe potential clinical and pathological factors associated with PSPD. Results: A total of 169 patients treated with anti-PD(L)-1 were included in the study. Most frequent tumor types included melanoma (n = 57) and non-small cell lung cancer (n = 19). At first tumor evaluation 77 patients (46%) presented with immune unconfirmed progressive disease. Six patients (8%) experienced PSPD: 2 patients with partial response; 4 patients with stable disease. Increase in target lesions in the first CT-scan was more frequently associated to PSPD (67% vs 33%; P = .04). Patients with a PSPD had a superior survival when compared to patients progressing (median OS: 10.7 months vs 8.7 months; P = .07). Conclusions: A small subset of PSPD patients may experience response after an initial progression. Assessment of the current strategy for immune-related response evaluations may require further attention.es_ES
dc.description.sponsorshipThe authors declare no funding for this study.es_ES
dc.subjectImmune checkpoint inhibitores_ES
dc.subjectResponse evaluation criteria in solid tumorses_ES
dc.subjectTreatment beyond progressiones_ES
dc.titleEvidence of pseudoprogression in patients treated with PD1/ PDL1 antibodies across tumor typeses_ES
dc.description.noteCC-BY. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.es_ES
dadun.citation.publicationNameCancer Medicinees_ES

Ficheros en este ítem:
Vista previa
Cancer Medicine - 2020 - Martin‐Romano - Evidence of pseudoprogression in patients treated with PD1 PDL1 antibodies across.pdf
362.04 kB
Adobe PDF

Estadísticas e impacto

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.